These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17066426)

  • 1. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
    Suspitsin EN; Sokolenko AP; Togo AV; Lazareva YR; Turkevich EA; Matsko DE; Henrich KO; Borresen-Dale AL; Schwab M; Cornelisse CJ; Imyanitov EN
    Int J Cancer; 2007 Jan; 120(2):297-302. PubMed ID: 17066426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas.
    Iyevleva AG; Kuligina ESh; Mitiushkina NV; Togo AV; Miki Y; Imyanitov EN
    Breast Cancer Res Treat; 2012 Feb; 131(3):1049-59. PubMed ID: 22057972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
    Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
    Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.
    Janssen JW; Cuny M; Orsetti B; Rodriguez C; Vallés H; Bartram CR; Schuuring E; Theillet C
    Int J Cancer; 2002 Dec; 102(6):608-14. PubMed ID: 12448002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
    Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
    Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas.
    Imyanitov EN; Suspitsin EN; Grigoriev MY; Togo AV; Kuligina ESh; Belogubova EV; Pozharisski KM; Turkevich EA; Rodriquez C; Cornelisse CJ; Hanson KP; Theillet C
    Int J Cancer; 2002 Aug; 100(5):557-64. PubMed ID: 12124805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
    Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
    J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction.
    Bièche I; Franc B; Vidaud D; Vidaud M; Lidereau R
    Thyroid; 2001 Feb; 11(2):147-52. PubMed ID: 11288983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.
    Freier K; Joos S; Flechtenmacher C; Devens F; Benner A; Bosch FX; Lichter P; Hofele C
    Cancer Res; 2003 Mar; 63(6):1179-82. PubMed ID: 12649172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amplification of oncogenes HER2, mdm-2 and myc in breast cancer determined by modified competitive PCR].
    Deng GR; He LW; Lu YY
    Zhonghua Yi Xue Za Zhi; 1995 Feb; 75(2):100-3, 127. PubMed ID: 7767763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer.
    Bolufer P; Molina R; Ruiz A; Hernandez M; Vazquez C; Lluch A
    Clin Chim Acta; 1994 Sep; 229(1-2):107-22. PubMed ID: 7988041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
    Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
    J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.